Abstract
The expression and activity of enzymes that belong to the aldehyde dehydrogenases is a characteristic of both normal and malignant stem cells. ALDH1A1 is an enzyme critical in cancer stem cells. In acute myeloid leukemia (AML), ALDH1A1 protects leukemia-initiating cells from a number of antineoplastic agents, which include inhibitors of protein tyrosine kinases. Furthermore, ALDH1A1 proves vital for the establishment of human AML xenografts in mice. We review here important studies characterizing the role of ALDH1A1 in AML and its potential as a therapeutic target. We also analyze datasets from leading studies, and show that decreased ALDH1A1 RNA expression consistently characterizes the AML patient risk group with a favorable prognosis, while there is a consistent association of high ALDH1A1 RNA expression with high risk and poor overall survival. Our review and analysis reinforces the notion to employ both novel as well as existing inhibitors of the ALDH1A1 protein against AML.
1. Introduction
Acute myeloid leukemia is a clonal hematopoetic disease that is associated with a high death rate in pediatric (>30%) as well as in adult (>50%) patients. In adults AML is the most common form of acute leukemia, and has the shortest survival, with less than 25% of patients surviving five years after diagnosis [1]; [2]; [3]. AML can be classified into primary, de novo AML, which arises in the absence of an identified exposure or prodromal stem cell disorder and non-denovo AML; non-denovo includes secondary AML, representing transformation of an antecedent diagnosis of myelodysplastic syndrome (MDS) or myeloproliferative neoplasm, therapy-related AML developing as a late complication in patients with prior exposure to leukemogenic therapies [4]. From a biological and therapeutic standpoint, relapsed AML should also be included in non-de novo AML, as it involves discrete, traceable changes [5] from primary AML.
Although AML is genetically heterogeneous, it involves a rather small number of genetic alterations and certain molecular patterns prove common to both adult as well as to pediatric patients [6]; [7]. The World Health Organization defines specific acute myeloid leukemia (AML) disease entities by focusing on significant cytogenetic and molecular genetic subgroups: a large number of recurring, balanced cytogenetic abnormalities are recognized in AML, and most of those that are not formally recognized by the classification are rare [8].
1.1. Classification of AML into prognostic risk groups
The primary prognostic factor in AML is cytogenetics, due to the fact that the clinical course of AML is largely determined by the presence of specific chromosomal aberrations in the cell nucleus. Depending on the types of chromosomal aberrations present, AML patient cases were classified into low risk, intermediate risk, and high risk. Cases with no detected chromosomal aberrations are classified into the intermediate risk group, while cases with detected aberrations are classified into any one of the three categories. Specifically AML associated with t(8;21), t(15;17) or inv(16) predicted a relatively favorable outcome. Whereas in patients lacking these favorable changes, the presence of a complex karyotype, -5, del(5q), -7, or abnormalities of 3q defined a group with relatively poor prognosis. The remaining group of patients including those with 11q23 abnormalities, +8, +21, +22, del(9q), del(7q) or other miscellaneous structural or numerical defects not encompassed by the favorable or adverse risk groups were found to have an intermediate prognosis [9].
In 2010, an international expert panel, on behalf of the European LeukemiaNet (ELN), published recommendations for diagnosis and management of acute myeloid leukemia (AML), which integrated cytogenetics with mutational screening for the genes NPM1, FLT3, and CEBPA that improved classification. The risk groups were defined as low-risk, intermediate I, intermediate II, and high-risk (or with reference to prognosis as favorable, intermediate 1, intermediate 2, and adverse) [10].
These recommendations have been widely adopted in general practice, within clinical trials, and by regulatory agencies. The original intention of the ELN genetic categories was to standardize reporting of genetic abnormalities particularly for correlations with clinical characteristics and outcome.
During recent years, considerable progress has been made in understanding disease pathogenesis, and in development of diagnostic assays and novel therapies. In 2017, the panel decided to simplify the ELN system by using a 3-group classification (favorable, intermediate, adverse) rather than the previous 4-group system; in parallel, mutational screening for genes RUNX1, ASXL1, and TP53 was added to the prognostic criteria [11].
1.2. Cellular developmental changes affect the response to treatment
Even though AML was among the first malignancies to show durable remission with adoptive therapy though transplantation of healthy stem cells, there is a paucity of information on the effects of therapeutic agents on key factors that shape the leukemia microenvironment [12]. Furthermore, there is a need of a deeper molecular understanding that would lead to treatments targeted to the leukemia-initiating cells (or “leukemia stem cells”) that appear linked to the most severe and difficult to treat manifestations of AML [13].
The myeloid progenitor cells arise from hematopoietic stem cell by asymmetric division. In turn the myeloid progenitor cells give rise to myeloblasts. An abnormal clone that develops from either a myeloid progenitor cell or a myeloblast can give rise to acute myeloid leukemia [14]. Characteristically, internal tandem duplications of the FLT3 gene are present in AML stem cells, and support key leukemia-initiating cell properties, which are experimentally shown by engraftment into mice [15]. Patients with AML cells expressing a primitive stem cell phenotype (CD34+CD38-with high aldehyde dehydrogenase activity) manifest significantly lower complete remission rates, as well as poorer event-free and overall survivals [16]. In AML, signaling from the bone marrow microenvironment of normal hematopoietic stem cells and leukemia-initiating cells has a pivotal role in the biology of the disease [17]. Deficient signaling from the vitamin A derivative, all-trans retinoic acid in the hematopoietic microenvironment in mice was shown to cause a myeloproliferative syndrome with significant reduction in the numbers of B lymphocyte subsets and erythrocytes in the bone marrow [18].
In patients with acute promyelocytic leukemia, high blast cell counts and failure to respond to differentiation treatment was associated with low all-trans retinoic acid plasma concentrations, and a high rate of clearance [19]. For the other types of AML, and despite its importance in controlling myeloid differentiation and apoptotic pathways, all-trans retinoic acid has yet to prove itself as a useful agent in the armamentarium of AML therapeutics. The explanation probably lies in the fact that retinoic acid receptor is expressed, but of limited functionality in AML blast cells [20]. However there are both positive and negative associations of CD34+ immature blast cells with sensitivity to all-trans retinoic acid [21]; [22].
2. Aldehyde dehydrogenases in AML
2.1. Implication of the enzymatic activity of aldehyde dehydrogenases in AML development and progression
Aldehyde dehydrogenases are enzymes that oxidize aldehydes to carboxylic acids. Member proteins of the subfamily ALDH1 metabolize the retinaldehyde, the product of oxidation of vitamin A, into retinoic acid, which binds to the retinoic acid receptors α, β, and γ, to activate them as regulators of gene expression. This function helps differentiation of diverse cell types, and primes tissues for repair, regrowth and regeneration after inflammation or injury, and activates genes of the HOX family, which in turn activate cellular programs of positional memory during embryogenesis and regeneration [23].
In the organism, ethanol is metabolized to acetaldehyde that interferes with systems that protect cells from oxidant stress. ALDH proteins oxidize acetaldehyde to acetate, protecting cells and tissues from oxidative damage and helping maintain tissue function. However, ALDH proteins protect both normal as well as malignant stem cells (cancer stem cells) from reactive aldehydes and certain cytotoxic drugs such as cyclophosphamide [24]; [25].
Evidence has been mounting that the protein family of the aldehyde dehydrogenases plays a role in the development of AML, although the interpretation of their exact biological effect on AML progression remains controversial [26]. Higher ALDH activity was shown in normal hematopoietic stem cells, when compared to AML stem cells in a study of 32 patients and five bone marrow donors [27]. In a larger sample size (n=104), a minority of patients (24 of 104) had numerous ALDH-positive leukemic stem cells that could not be separated from normal hematopoietic stem cells, were drug-resistant, and had high efficiency of xenograft formation in mice [28]. Nevertheless, cases with increased fractions of ALDH-positive AML cells were shown to derive from immature hematopoietic progenitors, suggesting an explanation for the poor prognosis and therapy resistance of this subgroup, which was attributed to the transmission of stem cell properties [29][30].
2.2. Overview and function of ALDH1A1
ALDH family member ALDH1A1, encoded in chromosome 9q21, is the enzyme of the second step of the main oxidative pathway of alcohol metabolism; ALDH1A1 may also catalyze the oxidation of toxic lipid aldehydes such as 4-hydroxynonenal and malonaldehyde, and is the enzyme responsible for production of retinoid acid during the late stages of dorsal eye development [31]. Notably, citral and disulfiram, an FDA-approved drug to treat alcohol use disorder, inhibit human lens ALDH1A1 at IC50 values of the micromolar range [32]. In neoplasia, in addition to its known enzymatic activity, ALDH1A1 supports tumor growth via glutathione/dihydrolipoic acid-dependent NAD + reduction [33]. ALDH1A1 is elevated in hematopoietic stem cells, is a predominant ALDH isoform in mammalian tissues, and the key ALDH isozyme linked to both normal and malignant stem cells [34]. ALDH1A1 in hematopoietic stem cells metabolizes reactive aldehydes and reactive oxygen species, and has a potential role in protection of neurons from 3,4-dihydroxyphenylacetaldehyde [35]. Consequently, decreased expression of ALDH1A1 has been linked to the development of Parkinsons’ disease [36].
Furthermore, the ALDH1A1 protein is a critical enzyme for maintaining clarity in human, rat, and mouse lenses; ALDH1A1-null mice grow to adulthood, but develop cataracts later in life (by six to nine months of age;) [37]; [38]; [32]. Hematopoietic cells from ALDH1A1-deficient mice exhibit increased sensitivity to liver metabolites of cyclophosphamide; however, ALDH1A1 deficiency did not affect the function of stem cells from the hematopoietic and nervous system [39].
2.3. Regulation of ALDH1A1 gene expression
Expression of the gene ALDH1A1 is regulated by the transcription factor EVI1 (Ecotropic virus integration site-1), which has an outstanding role in the formation and transformation of hematopoietic cells; a meta-analysis suggested that EVI1 is associated with an adverse prognosis in AML, and specifically in patients that belong to the intermediate risk group according to cytogenetic criteria of the European LeukemiaNet (ELN) [40]; [41]; [42]. Another transcription factor implicated in ALDH1 regulation is nuclear factor kappa B (NFκB) a factor found constitutively active in malignant myeloblast cells of AML [43]; [44]; [45]. Cells normally activate NFκB in response to inflammatory stimuli and disruptions of tissue function [46].
To activate ALDH1A1 expression indirectly, NFκB induces expression of micro RNA223-3p, which inhibits expression of ARID1A. ARID1A loss, in turn allows histone acetylation of the ALDH1A1 gene promoter [47]; [48]. Having an established capacity to guide epigenetic changes that guide leukemic stem cell programs, NFκB has been associated with cancer recurrence, and with AML relapse [49]; [50]; [51]; [52].
2.4. An elusive role for ALDH1A1 expression in AML
In AML the expression of RNA from the ALDH1A1 gene was implicated in resistance of AML to the protein kinase inhibitor sorafenib in FLT3-mutated AML, which normally shows potent FLT3-ITD (internal tandem duplication) inhibitory activity [53] ; [54]. Specifically, nonobese diabetic/severe combined immunodeficiency mice (NOD/SCID) transplanted with leukemia cells from patients before and during sorafenib resistance recapitulated the clinical results: The CD34+ALDH+ fraction preferentially expressed ALDH1A1 and exhibited superior engraftment compared with the CD34+ALDH-population when transplanted to NOD/SCID mice at equal cell doses. Forced expression of ALDH1A1 enhances the colony-forming capacity of leukemia cell lines 697(EU3) and HL60/S4 [55].
ALDH1A1 overexpression has also been associated with sorafenib resistance in other malignancies [56]. Interestingly however, in a study of primary AML cells from 21 patients, ALDH1A1 transcripts were highest in the ALDHneg leukemic cells [57]. On the other hand, in mouse xenografts, use of an irreversible inhibitor of ALDH1 eradicated specifically human AML cells and spared healthy mouse hematologic cells; in vitro, selectively the inhibitor was cytotoxic in a leukemic population enriched in stem cells, but unlike conventional chemotherapy, it was not toxic for healthy hematopoietic stem cells [58]. Furthermore, increased expression of ALDH1A1 was shown to confer to AML cells resistance to reactive aldehydes and reactive oxygen species, and associated with a worse prognosis in AML patients of The Cancer Genome Atlas (TCGA) study [59].
From all of the above data it can be concluded that the ALDH gene family has been implicated in the biology of AML; however, data on the important isoform ALDH1A1 have not been entirely conclusive in regard to the exact effect of ALDH1A1 expression on AML prognosis. We therefore sought to characterize the relationship between ALDH1A1 expression, cytogenetic risk group, and prognosis by examining publicly available datasets.
3. Cross-dataset analysis
3.1. Patient cohorts and data processing
We searched the literature and the Gene Expression Omnibus [60] for publicly available AML gene expression datasets that included risk or survival information. We identified 8 cohorts with risk information (N = 1473) and 7 with overall survival information (N = 1170). The cohorts we analyzed are summarized in Table 1. Two datasets, GSE12417 and GSE10358, were identified but were excluded from our analysis because they contain duplicate data. In particular, GSE12417 contains patients from the AMLCG trial which are profiled in GSE37642, and GSE10358 contains data from TCGA. We note that we limited our analysis to differential expression (across risk groups) and overall survival analysis since other variables (such as treatment assignment and response) were not consistently reported.
RNA-seq count data was downloaded for the TCGA and TARGET cohorts. TCGA data was downloaded from Firehose [61]. TARGET expression data was downloaded from the Genomic Data Commons [62]) and clinical information downloaded from cBioPortal [63]. RNA-seq count data was processed using R. First, low expressing genes (<15 read counts across samples) were removed. Counts were normalized using the TMM method using the edgeR package [64], and then converted to counts per million (CPM) on the log scale [65]. BEAT AML data was imported into R using the beatAML package (https://github.com/radivot/AMLbeatR) and filtered to include only initial leukemia samples. The dataset was then split into two cohorts, for patients with bone marrow aspirate (BMA) samples and patients with peripheral blood (PB) samples. Patients with both BMA and PB samples (N = 17) were excluded from downstream analysis, so that the BMA and PB cohorts could be analyzed independently. All other expression data was downloaded from the Gene Expression Omnibus [60] and analyzed using R.
3.2. AML patient risk groups are associated with overall survival
We first confirm that assigned risk groups are associated with patient outcomes by generating Kaplan-Meier curves for the 6 cohorts with both survival and risk information (Figure 1). Risk status was determined using ELN 2017 criteria with labels provided by the original authors. In 5/6 cohorts, risk status is significantly able to stratify patients (logrank P < 0.01), with the patients in the “favorable” or “low” risk group having a longer survival. In one cohort, BEAT AML (PB), the result is not statistically significant, but patients in the “favorable” risk group generally have better outcomes. These results demonstrate that, as expected, risk status is associated with outcome in the cohorts we examine.
3.3. ALDH1A1 RNA expression levels in AML patient risk groups
We next examined the relationship between ALDH1A1 RNA expression level and risk group, and find that expression consistently differs across risk groups (P < 0.01) in 8 patient cohorts. In all cases, ALDH1A1 expression is the lowest in the “favorable” or “low” risk group (Figure 2).
3.4. ALDH1A1 RNA association with AML patient overall survival
A survival analysis was carried out to determine whether ALDH1A1 expression was associated with overall survival of AML patients. For each cohort, patients were stratified based on whether their ALDH1A1 expression level was high (≥ median) or low (< median). A forest plot summarizing the survival analysis for the 7 cohorts is given in Figure 3. In each case the HR > 1, indicating that low expression is consistently associated with a more favorable outcome, and this relationship is statistically significant in 3 cohorts (P < 0.05). Additionally, the HR has a weighted average of 1.42 (95% CI, 1.22 – 1.66), which is statistically significant (P < 0.05).
4. Discussion
4.1. Biological mechanisms associated with ALDH1A1 suggest a path for new treatment strategies
Expression of the ALDH1A1 gene, and the consequent activity of the resulting ALDH1A1 protein influence a number of distinct biological functions, either directly or indirectly. ALDH1A1 is an essential enzyme for development and maintenance of tissue homeostasis, yet its overexpression is evidently linked to the development and progression of AML. We here discuss a few representative phenomena that implicate ALDH1A1 gene expression, with focus on functions that have a marked impact on AML disease course.
4.2. ALDH1A1 activation of the myeloid stem cell lineage associates with severe disease course
A critical discovery was made when it was demonstrated that overexpression of ALDH1A1 promoted myelopoiesis, while inhibiting lymphopoiesis in murine hematopoietic progenitors. This finding can explain the uniform association of ALDH1A1 overexpression with the poor prognosis in AML, as it could be interpreted with the hypothesis that in poor-prognosis AML, ALDH1A1 RNA is expressed far above the level that is required for the myeloid lineage. This overexpression could be due to higher activity of transcription factors such as TLX1/HOX11 and alternatively, NFκB [66]. Dysregulation of either one of these factors has been associated with a severe course of AML [67]; [68]. In particular NFκB has been characterized as a factor with an important role in the control of AML stem and progenitor cells, with a vital function in the regulation of interactions between AML cells and their microenvironment [69]; [70]; [52]; [71].
4.3. AML stem cells are maintained by signaling through FLT3 and NFκB
In AML, constitutive NFκB DNA-binding activity is frequently mediated by a Ras/PI3-K/PKB-dependent pathway [72]. Also overexpression of FLT3 induces NFκB-dependent transcriptional activity in cultured cells [73]. The constitutive activation of FLT3-ITD induces NFκB activity [74]. And conversely, FLT3 inhibition or knockdown reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and AML [75]. NFκB is regulated by changes in cellular proteostasis; its native inhibitor, the IkB protein can be degraded by cellular proteolytic systems such as the proteasome or the lysosome, which are mutually regulated through the induction of transcription factors [76]; [77]. In fact, induction of cell stress combined with NFκB inhibition is a promising approach in AML treatment, due to the connection between proteostatic pathways activated by cell stress and those inducing NFκB activity, as was recently shown in a clinical trial of relapsed patients with acute promyelocytic leukemia [78]; [79].
One agent that is used in treatment of AML, is the nucleoside cytosine arabinoside [80]. In fact, cytosine arabinoside (cytarabine, ara-C), in high concentrations (>50uM) inhibits NFκB in some cell types to a certain extent; yet this inhibition is evidently not enough, since after development of drug resistance, ara-C does not suffice as monotherapy for AML [81]; [82]; [83].
On the one hand, mutated, constitutively active FLT3, activates signaling molecules RAS, and PI3K/mTOR which activate NFκB [84]. On the other hand, AML can develop resistance against all inhibitors of FLT3 at some point [85]. Consequently, combination of NFκB and FLT3 inhibitors has been previously suggested by in vitro and xenograft studies of AML cells from patients [86]; [87]. An additional reason to combine inhibitors is the fact that NFκB causes epigenetic changes in nuclear chromatin, which cannot be reversed by inhibition of NFκB itself in the affected cells [88]. Downstream target genes of NFκB-guided transcription, therefore, such as ALDH1A1, are attractive aims for AML treatment.
4.4. ALDH1A1 protects malignant cells and modulates effects of AML chemotherapy
ALDH1A1 causes resistance to several antineoplastic treatments. A number of agents, such as paclitaxel, doxorubicin, sorafenib and staurosporine, promote oxidant-stress and thereby cause cell death; both phenomena are inhibited by ALDH1A1 expression [56]. Conversely, under conditions that ALDH1A1 is inhibited, resistance of cancer cells to cytarabine is decreased and cells become sensitive to the drug. For AML, disulfiram was found to suppress cytarabine resistance of cells with high aldehyde dehydrogenase activity, and to inhibit their engraftment in mice, while sparing healthy blood cells [89]. Thus AML is dependent on ALDH1 activity, and more sensitive to ALDH1 inhibition than the normal hematopoietic system.
ALDH1A1 leading to the myeloid lineage would be consistent with an increased lysosomal capacity, and a chemoresistant profile of the resulting cells [90]; [91]; [92]; [93]. In fact, autophagy supplies AML cells with lipid degradation products, which fuel oxidative phosphorylation in a manner that is absent in normal cells [94]. Even inhibition of NFκB conveys ara-C sensitivity more effectively to bulk AML cells than to leukemia stem cells, while stem and progenitor AML gains in resistance, presumably via lysosomal pathway activation: this is shown by the synergy between mTOR inhibitors and autophagy inhibitors in killing AML cells [95]; [96]. However, ALDH1A1 overexpression was found to enhance lysosomal autophagy inhibitor cell entry and cytotoxicity, without directly affecting lysosome function or autophagic flux [97]. Furthermore, inhibition of autophagy did not convert AML cells from ara-c resistance to sensitivity [98]. This can be explained by an increased capacity of ara-c resistant AML to respond to the oxidative DNA damage that is caused by ara-c, and by a contribution of ALDH1A1 to the detoxification of reactive aldehydes that would otherwise saturate the DNA with oxidative lesions.
In fact, relapse in AML was previously associated with increases in advanced oxidation protein products, malondialdehyde, and 8-hydroxydeoxyguanosine, and decreased total antioxidant capacity in patients’ plasma [99]. Constitutively active FLT3, in particular increases reactive oxygen species production leading to increased DNA double-strand breaks and DNA repair errors that may explain aggressive AML [100]. In particular, genomic instability is a principle pathologic feature of AML with internal tandem duplications of the FLT3 gene, which is characterized by poor prognosis [101]. AML cells adapt to oxidant stress by adapting sphingolipid metabolism, fatty acid oxidation, purine metabolism, amino acid homeostasis and glycolysis [102]. However, oxidant stress alters the cellular microenvironment, by inducing the expression of cytokines and chemokines:
Reactive aldehydes and reactive oxygen species generate oxidative damage on DNA, which activates repair enzyme binding to DNA. When increased on the cell, oxidant stress temporarily inactivates base excision repair enzyme 8-oxoguanine glycosylase (OGG1), which recruits transcription factor NFκB to induce expression of inflammatory genes [103]. This effect has profound effects in RAS/NFκB-dependent carcinogenesis, by modulating interactions between cancer cells, their microenvironment, and the immune system, causing immunosuppression [2]; [104]. In hepatocarcinogenesis, fluctuations of ALDH1A1 and NFκB are observed, concomitantly with OGG1 [105]. In AML, OGG1 expression correlates with adverse cytogenetics, and has a more adverse impact on disease outcome in the context of the FLT3-ITD mutation [106], a context shared with ALDH1A1 [54]. In fact, OGG1 affects resistance of AML to cytarabine: OGG1-deficient acute myeloid leukemia cells have increased sensitivity to cytarabine [107].
It can be therefore concluded that reactive oxygen species are essential to the effects of certain chemotherapeutic agents, and increases in ALDH1A1 cause resistance to these agents and facilitate relapse of AML. However, in other cancers ALDH1A1 expression was linked to the expression of PD-L1, a molecule that suppresses T-lymphocyte mediated immunity [108]; [109]. PDL-1 is expressed in the microenvironment of AML, where it promotes expansion of the immunosuppressive regulatory T-cells [110]; [111]; [112]. If the same PD-L1 inducing effect of ALDH1A1 occurs also in AML as in other cancers (Supplementary Figure S1), then high ALDH1A1 expression in cases with adverse prognosis may be linked to immune evasion, in addition to the well-characterized effects of ALDH1A1 on antineoplastic agents.
4.5. Implications for treatment
Novel selective inhibitors for ALDH1A1 are under development [113]; [114]; [115]; [116]. In other malignancies, clinical trials evaluating the ALDH1A1 inhibitor disulfiram in glioblastoma have been registered (U.S. National Library of Medicine resource platform ClinicalTrials.gov registration numbers NCT01777919, NCT02770378, NCT01907165, NCT03363659, NCT02678975, NCT03151772, NCT03034135, NCT02715609; for an overview see https://clinicaltrials.gov/ct2/results?term=disulfiram&cond=Cancer). Other, experimental inhibitors of ALDH1A1 should enter translational research for the development of AML treatments. A success in this endeavor would be especially important for patients with poor-prognosis, including those experiencing disease relapse and resistance to chemotherapy and biologically targeted therapy.
Additionally, the consistent up-regulation of ALDH1A1 expression in patients with non-favorable risk across a wide range of patient cohorts (Figure 2) suggests that such a treatment may benefit a wide variety of patient groups.
Data Availability
All data produced in the present work are contained in the manuscript.
Declaration of Competing Interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Acknowledgements
Authors wish to thank the AMLCG study group for help in this project. This work was supported, in part, by a grant from the American Association of University Professors and Connecticut State University Board of Regents (YRDA01).
Abbreviations
- AKT/PKB
- RAC-alpha serine/threonine-protein kinase
- ALDH
- Aldehyde dehydrogenase
- AML
- Acute myeloid leukemia
- ara-c
- cytosine arabinoside
- CEBPA
- CCAAT enhancer binding protein alpha
- del
- deletion
- ELN
- European LeukemiaNet
- EVI1
- ecotropic viral integration site 1
- FLT3
- Fms-like tyrosine kinase-3
- FLT3 ITD
- internal tandem duplication of FLT3
- inv
- inversion
- MTOR, kinase
- mechanistic/mammalian target of rapamycin
- NFκB
- nuclear factor kappa B
- NOD/SCID
- nonobese diabetic/severe combined immunodeficiency mice
- NPM1
- nucleophosmin 1
- OGG1
- 8-oxoguanine glycosylase
- PD-L1
- Programmed death-ligand 1
- PI3K
- phosphatidylinositol 3-kinase
- t
- translocation
- TLX1/HOX11
- T cell leukemia/homeobox 1
References
- 1.↵
- 2.↵
- 3.↵
- 4.↵
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- 9.↵
- 10.↵
- 11.↵
- 12.↵
- 13.↵
- 14.↵
- 15.↵
- 16.↵
- 17.↵
- 18.↵
- 19.↵
- 20.↵
- 21.↵
- 22.↵
- 23.↵
- 24.↵
- 25.↵
- 26.↵
- 27.↵
- 28.↵
- 29.↵
- 30.↵
- 31.↵
- 32.↵
- 33.↵
- 34.↵
- 35.↵
- 36.↵
- 37.↵
- 38.↵
- 39.↵
- 40.↵
- 41.↵
- 42.↵
- 43.↵
- 44.↵
- 45.↵
- 46.↵
- 47.↵
- 48.↵
- 49.↵
- 50.↵
- 51.↵
- 52.↵
- 53.↵
- 54.↵
- 55.↵
- 56.↵
- 57.↵
- 58.↵
- 59.↵
- 60.↵
- 61.↵
- 62.↵
- 63.↵
- 64.↵
- 65.↵
- 66.↵
- 67.↵
- 68.↵
- 69.↵
- 70.↵
- 71.↵
- 72.↵
- 73.↵
- 74.↵
- 75.↵
- 76.↵
- 77.↵
- 78.↵
- 79.↵
- 80.↵
- 81.↵
- 82.↵
- 83.↵
- 84.↵
- 85.↵
- 86.↵
- 87.↵
- 88.↵
- 89.↵
- 90.↵
- 91.↵
- 92.↵
- 93.↵
- 94.↵
- 95.↵
- 96.↵
- 97.↵
- 98.↵
- 99.↵
- 100.↵
- 101.↵
- 102.↵
- 103.↵
- 104.↵
- 105.↵
- 106.↵
- 107.↵
- 108.↵
- 109.↵
- 110.↵
- 111.↵
- 112.↵
- 113.↵
- 114.↵
- 115.↵
- 116.↵